drugset / Trial / NCT06807905

Efficiency and Biocompatibility in Hemodiafiltration Procedure

NCT06807905

Phase 4 Completed 20 enrolled University Medical Centre Ljubljana
RandomizedCrossoverOpen-labelTreatment

Summary

Hemodiafiltration is a modern, increasingly used special hemodialysis method. Compared to hemodialysis, it allows greater clearance of medium- and high-molecular-weight molecules. Modern hemofiltration membranes are approaching the properties of the glomerular membrane in their properties. During hemodiafiltration, blood contact with the semipermeable membrane and blood lines causes activation of the coagulation system, so anticoagulation during the procedure is absolutely necessary. Heparin is routinely used as a method of anticoagulation in hemodiafiltration. Regional citrate anticoagulation is used primarily in patients with risk of bleeding. The purpose of our study is to evaluate the kinetics of citrate, calcium, and magnesium during hemodiafiltration and citrate anticoagulation, and in these way optimizing the citrate anticoagulation protocol during hemodiafiltration, and to compare the clearance of small and medium molecules between the two anticoagulations (citrate and heparin). The purpose of the study is also to compare biocompatibility parameters for heparin and citrate anticoagulation in hemodiafiltration.

Timeline

Start
2019-02-01
Primary completion
2020-09-01
Completion
2021-02-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Heparin Other / unclassified
Subject citrate Unknown 8 %